Skip to main content
Journal cover image

Cancer Outcomes in DCIS Patients Without Locoregional Treatment.

Publication ,  Journal Article
Ryser, MD; Weaver, DL; Zhao, F; Worni, M; Grimm, LJ; Gulati, R; Etzioni, R; Hyslop, T; Lee, SJ; Hwang, ES
Published in: J Natl Cancer Inst
September 1, 2019

BACKGROUND: The vast majority of women diagnosed with ductal carcinoma in situ (DCIS) undergo treatment. Therefore, the risks of invasive progression and competing death in the absence of locoregional therapy are uncertain. METHODS: We performed survival analyses of patient-level data from DCIS patients who did not receive definitive surgery or radiation therapy as recorded in the US National Cancer Institute's Surveillance, Epidemiology, and End Results program (1992-2014). Kaplan-Meier curves were used to estimate the net risk of subsequent ipsilateral invasive cancer. The cumulative incidences of ipsilateral invasive cancer, contralateral breast cancer, and death were estimated using competing risk methods. RESULTS: A total of 1286 DCIS patients who did not undergo locoregional therapy were identified. Median age at diagnosis was 60 years (inter-quartile range = 51-74 years), with median follow-up of 5.5 years (inter-quartile range = 2.3-10.6 years). Among patients with tumor grade I/II (n = 547), the 10-year net risk of ipsilateral invasive breast cancer was 12.2% (95% confidence interval [CI] = 8.6% to 17.1%) compared with 17.6% (95% CI = 12.1% to 25.2%) among patients with tumor grade III (n = 244) and 10.1% (95% CI = 7.4% to 13.8%) among patients with unknown grade (n = 495). Among all patients, the 10-year cumulative incidences of ipsilateral invasive cancer, contralateral breast cancer, and all-cause mortality were 10.5% (95% CI = 8.5% to 12.4%), 3.9% (95% CI = 2.6% to 5.2%), and 24.1% (95% CI = 21.2% to 26.9%), respectively. CONCLUSION: Despite limited data, our findings suggest that DCIS patients without locoregional treatment have a limited risk of invasive progression. Although the cohort is not representative of the general population of patients diagnosed with DCIS, the findings suggest that there may be overtreatment, especially among older patients and patients with elevated comorbidities.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

September 1, 2019

Volume

111

Issue

9

Start / End Page

952 / 960

Location

United States

Related Subject Headings

  • Young Adult
  • Survival Analysis
  • SEER Program
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Grading
  • Middle Aged
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ryser, M. D., Weaver, D. L., Zhao, F., Worni, M., Grimm, L. J., Gulati, R., … Hwang, E. S. (2019). Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst, 111(9), 952–960. https://doi.org/10.1093/jnci/djy220
Ryser, Marc D., Donald L. Weaver, Fengmin Zhao, Mathias Worni, Lars J. Grimm, Roman Gulati, Ruth Etzioni, Terry Hyslop, Sandra J. Lee, and E Shelley Hwang. “Cancer Outcomes in DCIS Patients Without Locoregional Treatment.J Natl Cancer Inst 111, no. 9 (September 1, 2019): 952–60. https://doi.org/10.1093/jnci/djy220.
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2019 Sep 1;111(9):952–60.
Ryser, Marc D., et al. “Cancer Outcomes in DCIS Patients Without Locoregional Treatment.J Natl Cancer Inst, vol. 111, no. 9, Sept. 2019, pp. 952–60. Pubmed, doi:10.1093/jnci/djy220.
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, Etzioni R, Hyslop T, Lee SJ, Hwang ES. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2019 Sep 1;111(9):952–960.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

September 1, 2019

Volume

111

Issue

9

Start / End Page

952 / 960

Location

United States

Related Subject Headings

  • Young Adult
  • Survival Analysis
  • SEER Program
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Grading
  • Middle Aged
  • Humans
  • Female